当前位置:首页 - 行情中心 - 金陵药业(000919) - 财务分析 - 利润表

金陵药业

(000919)

  

流通市值:33.58亿  总市值:34.09亿
流通股本:5.03亿   总股本:5.11亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入2,104,243,523.411,441,396,813.35708,534,720.182,670,968,038.97
营业收入2,104,243,523.411,441,396,813.35708,534,720.182,670,968,038.97
二、营业总成本1,998,369,328.071,351,685,078.29659,050,743.172,600,648,078.48
营业成本1,654,965,813.771,128,972,949.26559,305,288.062,142,825,876.41
税金及附加13,278,640.218,888,272.764,095,974.319,407,307.66
销售费用64,376,722.4833,841,440.968,606,702.4485,998,866.14
管理费用239,351,332.25162,216,781.3376,594,425.41297,479,026.26
研发费用42,194,094.4627,631,172.5514,231,193.7874,170,064.98
财务费用-15,797,275.1-9,865,538.57-3,782,840.82-19,233,062.97
其中:利息费用141,816.2598,070.5513,101.21255,674.14
其中:利息收入16,971,880.2910,779,278.584,254,053.320,059,924.81
加:公允价值变动收益426,164.09-218,871.18710,754.56-27,143,286.8
加:投资收益15,459,127.36,611,677.811,892,371.6114,917,831.99
资产处置收益-78,489.41-37,537.83-62,580,525.17
资产减值损失(新)-620,210.52-690,439.68-408,360.39
信用减值损失(新)-6,995,729.42-4,026,627.57-1,306,378.89-2,464,023.7
其他收益9,291,686.367,835,393.868,458,972.9111,393,015.53
营业利润平衡项目0000
四、营业利润123,356,743.7499,185,330.4759,239,697.2130,012,383.07
加:营业外收入932,070.34427,928.9197,670.251,958,666.64
减:营业外支出700,760.92592,374.07457,461.244,200,808.51
利润总额平衡项目0000
五、利润总额123,588,053.1699,020,885.358,979,906.21127,770,241.2
减:所得税费用16,678,527.5714,075,666.399,654,531.9913,904,131.8
六、净利润106,909,525.5984,945,218.9149,325,374.22113,866,109.4
持续经营净利润106,909,525.5984,945,218.9149,325,374.22113,866,109.4
归属于母公司股东的净利润97,610,028.3777,522,521.9343,585,110.26105,281,854.89
少数股东损益9,299,497.227,422,696.985,740,263.968,584,254.51
(一)基本每股收益0.190.150.090.21
(二)稀释每股收益0.190.150.090.21
八、其他综合收益---12,548,679.49
归属于母公司股东的其他综合收益---12,548,679.49
九、综合收益总额106,909,525.5984,945,218.9149,325,374.22126,414,788.89
归属于母公司股东的综合收益总额97,610,028.3777,522,521.9343,585,110.26117,830,534.38
归属于少数股东的综合收益总额9,299,497.227,422,696.985,740,263.968,584,254.51
公告日期2023-10-312023-08-192023-04-292023-03-24
审计意见(境内)标准无保留意见
TOP↑